Cite

HARVARD Citation

    Tawfik, B. et al. (2021). Costs of treatment change following first-line somatostatin analog monotherapy among patients with neuroendocrine tumors. Journal of medical economics. pp. 1337-1345. [Online]. 
  
Back to record